Dilafor is in the process of identifying strategic partners interested in developing and commercializing tafoxiparin globally or regionally.

Please contact:
Lena Degling Wikingsson, CEO

“I am delighted that my 40 years’ preclinical and clinical research have reached this significant milestone. There is a great medical need for new treatments to address protracted labor and I hope that tafoxiparin will make a difference for all these pregnant women.”

Professor Gunvor Ekman Ordeberg, Founder and CMO at start of phase IIb